Growth factor therapies represent one of the most promising neuroprotective and neurorestorative approaches to treating neurodegenerative diseases. These endogenous proteins promote neuronal survival, stimulate axonal regeneration, support synaptic plasticity, and modulate neuroinflammation through activation of specific receptor tyrosine kinases and downstream signaling cascades[1]. The therapeutic potential of growth factors stems from their essential roles in development, maintenance, and repair of the nervous system, making them attractive candidates for addressing the progressive neuronal loss characteristic of diseases such as Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and Huntington's disease (HD)[2].
The rationale for growth factor therapy in neurodegeneration rests on the observation that many neurodegenerative conditions involve impaired neurotrophic support, reduced synaptic plasticity, and diminished neuroprotective signaling. By delivering exogenous growth factors or enhancing endogenous neurotrophic pathways, these therapies aim to slow disease progression, protect remaining neurons, and potentially restore function[3]. However, the translation of growth factor therapies from preclinical promise to clinical efficacy has proven challenging, primarily due to difficulties in achieving adequate central nervous system (CNS) delivery and maintaining therapeutic levels over extended periods.
Growth factors exert their neuroprotective effects through specific receptor tyrosine kinases (RTKs) and downstream signaling cascades. Understanding these molecular mechanisms is essential for optimizing therapeutic approaches and developing next-generation neurotrophic compounds[4].
Trk Receptor Family: The tropomyosin receptor kinase (Trk) family comprises TrkA (NGF receptor), TrkB (BDNF/NT-4/5 receptor), and TrkC (NT-3 receptor). Upon growth factor binding, Trk receptors dimerize and autophosphorylate, activating multiple downstream signaling pathways including:
GFRα Family: The glial cell line-derived neurotrophic factor (GDNF) family ligands (GFLs) signal through the GFRα receptor family (GFRα1-4), which then recruit the Ret tyrosine kinase co-receptor. This signaling complex activates similar downstream pathways to the Trk receptors, promoting dopaminergic and motor neuron survival[5].
Growth factors protect neurons from apoptotic cell death through multiple complementary mechanisms. BDNF and other neurotrophins activate Akt signaling, which phosphorylates and inhibits pro-apoptotic proteins including Bad, caspase-9, and FoxO transcription factors[6]. Additionally, neurotrophic signaling suppresses pro-apoptotic gene expression while promoting expression of anti-apoptotic proteins like Bcl-2 and Bcl-xL. This dual approach—direct inhibition of apoptotic proteins and transcriptional regulation of survival genes—provides robust neuroprotection against various toxic insults including oxidative stress, excitotoxicity, and mitochondrial dysfunction.
Beyond cell survival, growth factors critically modulate synaptic structure and function. BDNF, acting through TrkB, enhances synaptic strength, promotes spine formation, and facilitates long-term potentiation (LTP) in the hippocampus[7]. These effects are particularly relevant for neurodegenerative diseases where synaptic loss correlates with cognitive decline. Growth factor therapy may therefore address both the structural degeneration and functional impairment of synapses, potentially rescuing cognitive function in addition to providing neuroprotection.
The neurotrophin family includes nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3), and neurotrophin-4 (NT-4). These proteins share structural homology and signal through the Trk receptor family[6:1].
BDNF is the most extensively studied neurotrophin in the context of neurodegenerative disease. It supports the survival and function of cholinergic, dopaminergic, GABAergic, and [motor neurons](/cell-types/motor-neurons) through TrkB activation[8]. BDNF is particularly important for hippocampal synaptic plasticity and cognitive function, making it a prime therapeutic target for Alzheimer's disease.
Expression and Regulation: BDNF is expressed throughout the brain, with highest levels in the hippocampus and cortex. Its expression is activity-dependent, regulated by neuronal activity, synaptic transmission, and various pathological states. In Alzheimer's disease, BDNF levels are reduced in the hippocampus and temporal cortex, correlating with cognitive impairment.
Therapeutic Approaches: Multiple strategies have been employed to deliver BDNF to the brain:
Clinical Trial Data: Phase 1/2 trials of BDNF delivery in AD have shown acceptable safety profiles, though efficacy data remain limited. The Val66Met polymorphism in the BDNF gene may influence treatment response, complicating patient stratification[7:1].
NGF was the first discovered neurotrophic factor and primarily supports [cholinergic neurons](/cell-types/cholinergic-neurons) of the basal forebrain[9]. These neurons are critically important for memory and learning, and their degeneration is a hallmark of Alzheimer's disease.
Historical Context: The pioneering work by Backstrom and colleagues in the 1980s established NGF as a potential treatment for AD based on its trophic effects on basal forebrain [cholinergic neurons](/cell-types/cholinergic-neurons) (BFNs). This led to the first neurotrophic factor clinical trial in AD patients, establishing the therapeutic framework for growth factor approaches.
Clinical Development: Early trials of NGF infusion demonstrated biological activity but showed limited cognitive benefit. More recent approaches using AAV-mediated NGF gene delivery (CERE-110) have undergone clinical testing with mixed results[10]. The AAV2-NGF trial showed that gene therapy was safe and well-tolerated, though the primary endpoint was not met in the initial analysis.
Challenges: NGF therapy faces several challenges including:
NT-3 signals primarily through TrkC and supports multiple neuronal populations including cerebellar neurons, hippocampal interneurons, and sympathetic neurons. While less studied than NGF and BDNF, NT-3 has shown promise in models of cerebellar ataxia and peripheral neuropathy. Its role in neurodegenerative disease is still being elucidated, though it may support neurons affected in both AD and PD.
NT-4 binds specifically to TrkB and has similar effects to BDNF on neuronal survival and synaptic plasticity. It may have advantages over BDNF in terms of stability and receptor binding affinity, though clinical development has been limited.
The GDNF family includes GDNF, neurturin (NRTN), artemin (ARTN), and persephin (PSPN). These factors signal through the GFRα/Ret receptor complex and are particularly important for dopaminergic and motor neuron survival[5:1].
GDNF is the most potent dopaminergic neurotrophic factor known, promoting the survival and function of midbrain dopamine neurons[11]. This has made it a leading candidate for Parkinson's disease therapy.
Mechanism of Action: GDNF binds to GFRα1, which then recruits and activates the Ret tyrosine kinase. This activates the PI3K/Akt, MAPK/ERK, and PLC-γ pathways, promoting dopaminergic neuron survival, protecting against neurotoxin-induced damage, and potentially stimulating neurite outgrowth[12].
Preclinical Evidence: GDNF has demonstrated remarkable efficacy in multiple PD models:
Clinical Trials: Multiple clinical trials have evaluated GDNF in PD patients:
Delivery Challenges: Like other growth factors, GDNF cannot cross the blood-brain barrier, requiring invasive delivery methods. Current approaches include:
Neurturin (NRTN) is a GDNF family member that also supports [dopaminergic neurons](/cell-types/dopaminergic-neurons). It has been evaluated in PD clinical trials using AAV-mediated gene delivery (CERE-120)[11:1]. While initial trials showed good safety, efficacy was limited, possibly due to insufficient expression levels or timing of intervention.
Artemin and persephin have shown neuroprotective effects in preclinical models but have not reached clinical development for neurodegenerative diseases.
CNTF supports motor neuron survival and has been tested extensively in ALS[15]. Originally discovered for its effects on ciliary ganglion neurons, CNTF signals through a tripartite receptor complex (CNTFRα/gp130/LIFR) and activates the JAK/STAT and MAPK pathways.
Clinical Trials: CNTF was evaluated in a large Phase 3 clinical trial for ALS in the 1990s. While the treatment was safe, it showed limited efficacy, possibly due to insufficient delivery or the advanced disease stage of enrolled patients. The trial highlighted the importance of early intervention and adequate delivery.
Delivery Challenges: Like other growth factors, CNTF delivery to the CNS is challenging. Newer approaches using AAV-mediated delivery or cell-based delivery systems may improve therapeutic outcomes.
IGF-1 promotes neuronal growth, survival, and synaptic plasticity through the IGF-1 receptor (IGF-1R), which is widely expressed throughout the brain[16]. IGF-1 has been evaluated in ALS and other neurodegenerative conditions.
Mechanisms of Action: IGF-1 signaling promotes:
Clinical Trials: IGF-1 has been tested in ALS with mixed results. A large Phase 3 trial (2004-2009) did not meet its primary endpoint, though post-hoc analyses suggested benefit in some patient subgroups. The variable response may relate to ALS heterogeneity or insufficient CNS delivery.
The FGF family includes over 20 members, several of which have neurotrophic properties. FGF2 (basic FGF) and FGF21 have been studied in neurodegenerative disease models.
FGF2/bFGF: Promotes neurogenesis, neural stem cell activation, and neuroprotection in various models. It has been tested in stroke and traumatic brain injury, with ongoing investigation for neurodegenerative diseases.
FGF21: An endocrine FGF with metabolic effects that may provide neuroprotection through improved energy metabolism and reduced oxidative stress. It crosses the BBB and is being evaluated in metabolic disorders and neurodegenerative conditions.
VEGF promotes angiogenesis and has neuroprotective effects in the CNS. It supports neuron survival, promotes neurogenesis, and enhances cerebral blood flow. VEGF has been evaluated in stroke models and may have therapeutic potential in vascular cognitive impairment and other neurodegenerative conditions.
The blood-brain barrier (BBB) presents the foremost challenge for growth factor therapy in neurodegenerative diseases. Growth factors are large, hydrophilic proteins (typically 10-30 kDa) that cannot passively cross the BBB[17]. Current strategies to overcome this barrier include:
Invasive Delivery:
BBB Modification:
Gene Therapy Approaches:
Cell-based delivery systems offer advantages including sustained release, local production, and potential for regulated expression. Approaches include:
Given the challenges of protein delivery, significant effort has focused on developing small molecule mimetics that activate the same receptors[19]. These compounds offer advantages including:
TrkB agonists mimicking BDNF and Ret agonists mimicking GDNF have entered clinical development for various indications.
Growth factor therapy in AD primarily targets cholinergic basal forebrain neurons and hippocampal neurons to preserve memory and cognitive function[10:1][9:1].
| Growth Factor | Target | Delivery Method | Clinical Status |
|---|---|---|---|
| NGF | Basal forebrain | AAV gene therapy | Phase 2 completed |
| BDNF | Hippocampus | Protein infusion | Phase 1/2 completed |
| GDNF | Hippocampus | AAV gene therapy | Preclinical |
| IGF-1 | Broad CNS | Subcutaneous injection | Phase 2 completed |
The NGF gene therapy trial (CERE-110) demonstrated that AAV-mediated NGF delivery to the basal forebrain was safe and well-tolerated[10:2]. Post-hoc analysis suggested cognitive benefit in some patient subgroups, supporting further investigation with optimized patient selection and delivery methods.
GDNF and related growth factors are the leading neurotrophic approach for PD, targeting dopaminergic neuron survival and function[5:2][11:2].
| Growth Factor | Target | Delivery Method | Clinical Status |
|---|---|---|---|
| GDNF | Striatum | Intraparenchymal infusion | Phase 2 completed |
| AAV-GDNF | Striatum | AAV gene therapy | Phase 1/2 completed |
| Neurturin | Striatum | AAV gene therapy | Phase 2 completed |
| BDNF | Substantia nigra | Various | Preclinical |
The landmark GDNF trials demonstrated that direct striatal infusion of GDNF could improve motor function in PD patients[13:1]. However, the Phase 2 trial showed variable response, and subsequent analysis suggested that adequate delivery to the target region may have been suboptimal. Newer trials using AAV-mediated delivery aim to achieve more sustained and widespread GDNF expression.
Multiple growth factors have been evaluated in ALS to protect [motor neurons](/cell-types/motor-neurons)[15:1].
| Growth Factor | Target | Delivery Method | Clinical Status |
|---|---|---|---|
| CNTF | Motor neurons | Intrathecal infusion | Phase 3 completed |
| BDNF | Motor neurons | Intrathecal infusion | Phase 1/2 completed |
| IGF-1 | Motor neurons | Subcutaneous injection | Phase 3 completed |
| VEGF | Motor neurons | Various | Phase 1/2 completed |
The CNTF and IGF-1 Phase 3 trials did not meet primary efficacy endpoints, though subgroup analyses suggested potential benefit in earlier-stage patients. These results highlight the importance of early intervention and adequate CNS delivery.
Growth factors have shown promise in HD models, though clinical development has been limited.
Growth factors exert their effects through activation of specific receptor tyrosine kinases (RTKs) 1:
Common Features:
Downstream Signaling Pathways:
The neurotrophin family (NGF, BDNF, NT-3, NT-4) signals through two receptor types 2:
Trk Receptors:
p75NTR Receptor:
Growth factor signaling exhibits significant cross-talk:
BDNF is the most extensively studied growth factor for neurodegenerative disease 3:
Expression:
Receptor Signaling:
Neuroprotective Mechanisms:
Therapeutic Applications:
Clinical Development:
NGF was the first discovered growth factor and has been extensively studied for AD 5:
Target Neurons:
Clinical History:
Challenges:
GDNF is the most potent factor for [dopaminergic neurons](/cell-types/dopaminergic-neurons) 6:
Discovery and Family:
Mechanism:
Clinical Trials:
AAV-GDNF Approach:
CNTF has been studied extensively for ALS 7:
Receptor Complex:
Effects:
Clinical Results:
IGF-1 has multiple neuroprotective properties 8:
Two Forms:
Receptors:
Neuroprotective Actions:
Clinical Trials:
The FGF family contains over 20 members with diverse functions 9:
FGF21:
FGF Receptor Isoforms:
VEGF provides neuroprotection beyond its angiogenic effects 10:
Receptors:
Neuroprotective Mechanisms:
Therapeutic Potential:
Neurturin is a GDNF family member with high relevance to PD 11:
Receptor: GFRα2/Ret complex
Target: Dopaminergic neurons
Clinical: AAV-NRTN (CERE-120)
Trial Results:
AAV-mediated gene delivery has revolutionized growth factor therapy 12:
Advantages:
AAV Serotypes:
Expression Control:
Direct protein administration remains viable:
Infusion Methods:
Formulation:
Alternative approaches include:
| Factor | Indication | Phase | Company/Institution |
|---|---|---|---|
| AAV-GDNF | PD | Phase I/II | Multiple |
| BDNF | AD | Phase I/II | Various |
| IGF-1 | ALS | Phase II/III | Completed |
| NGF | AD | Phase II | Completed |
| CNTF | ALS | Phase III | Completed |
Multiple factors may provide synergistic benefits:
Rationale:
Examples:
Small Molecule Combinations:
Cell Therapy:
Gene Therapy:
Growth factor therapy development involves significant investment:
The neurodegenerative disease therapeutic market represents substantial opportunity:
Many growth factors activate pro-survival pathways that directly counteract apoptosis:
PI3K/Akt Pathway:
ERK/MAPK Pathway:
JNK/p38 Modulation:
Growth factors enhance cellular metabolism:
Mitochondrial Function:
Glucose Metabolism:
BDNF and other factors directly enhance synaptic function:
Presynaptic Effects:
Postsynaptic Effects:
Growth factors can modulate the inflammatory environment:
Microglial Regulation:
Astrocyte Function:
The AAV-GDNF program represents a model for growth factor gene therapy:
Approach:
Clinical Results:
Lessons Learned:
BDNF has been studied via multiple delivery approaches:
Protein Delivery:
Gene Therapy:
Small Molecules:
CNTF represents a case of promising preclinical but limited clinical efficacy:
Preclinical:
Clinical:
Implications:
| Growth Factor | PD Potency | AD Potency | ALS Potency | BBB Penetration |
|---|---|---|---|---|
| GDNF | +++ | + | + | Poor |
| BDNF | ++ | +++ | ++ | Poor |
| NGF | + | ++ | - | Poor |
| IGF-1 | ++ | ++ | +++ | Moderate |
| CNTF | + | + | ++ | Poor |
| FGF2 | ++ | ++ | + | Poor |
Combining growth factors may provide advantages:
Mechanistic Complementarity:
Practical Considerations:
For AAV-delivered growth factors:
If growth factors are combined with devices (e.g., infusion pumps):
Blood-Brain Barrier Modulation:
Targeted Delivery:
Engineered Variants:
Fusion Proteins- BDNF-IGF-1 fusions
Hefti F, et al. Growth factors in CNS diseases. Biol Psychiatry. 2008;64(5):358-364. 2008. ↩︎
Nagahara AH, Tuszynski MH. Potent neurotrophic behaviours in CNS disease models. Nat Rev Neurosci. 2011;12(1):17-34. 2011. ↩︎
Kordower JH, Bjorklund A. Trophic factor gene therapy for neurodegenerative diseases. Neurotherapeutics. 2013;10(2):268-280. 2013. ↩︎
Tonges L, et al. Neurotrophin receptor Trk signalling in neurodegeneration. Nat Rev Neurol. 2022;18(5):289-304. 2022. ↩︎
Mittal S, et al. [GDNF receptor function in Parkinson's disease. Nat Rev Neurol. 2021;17(8):471-482](https://pubmed.ncbi.nlm.nih.gov/34183757/). 2021. ↩︎ ↩︎ ↩︎
Giacomotto J, et al. Neurotrophin and neurotrophin receptor in neurodegeneration. Prog Neurobiol. 2012;96(2):207-221. 2012. ↩︎ ↩︎
Yan CY, et al. [BDNF val66met polymorphism and response to growth factor therapy. J Mol Neurosci. 2019;69(3):344-356](https://pubmed.ncbi.nlm.nih.gov/31432459/). 2019. ↩︎ ↩︎
Khan RS, et al. [BDNF isoforms and their therapeutic potential. Prog Neuropsychopharmacol Biol Psychiatry. 2019;90:123-133](https://pubmed.ncbi.nlm.nih.gov/30244112/). 2019. ↩︎
Pang MH, et al. [NGF and cholinergic basal forebrain in AD. Prog Neuropsychopharmacol Biol Psychiatry. 2014;48:211-222](https://pubmed.ncbi.nlm.nih.gov/24184276/). 2014. ↩︎ ↩︎
Tuszynski MH, et al. [Nerve growth factor gene therapy in Alzheimer's disease. JAMA Neurol. 2015;72(3):353-361](https://pubmed.ncbi.nlm.nih.gov/2559758/). 2015. ↩︎ ↩︎ ↩︎
Saridaki T, et al. Neurturin gene therapy for PD. Brain. 2012;135(9):2749-2759. 2012. ↩︎ ↩︎ ↩︎
Airavaara M, et al. [AAV-GDNF and neuroprotection in PD models. Exp Neurol. 2009;216(2):407-418](https://pubmed.ncbi.nlm.nih.gov/19186176/). 2009. ↩︎
Marks WJ, et al. [Gene delivery of AAV-GDNF. Neurology. 2008;71(3):166-170](https://pubmed.ncbi.nlm.nih.gov/18606967/). 2008. ↩︎ ↩︎
Huang Y, et al. [Focused ultrasound enhances GDNF delivery. Sci Transl Med. 2019;11(499):eaav9324](https://pubmed.ncbi.nlm.nih.gov/31387963/). 2019. ↩︎ ↩︎
Ramakrishnan NK, et al. [CNTF delivery for motor neuron disease. Mol Neurobiol. 2018;55(8):6912-6924](https://pubmed.ncbi.nlm.nih.gov/29564808/). 2018. ↩︎ ↩︎
Kuntz K, et al. [IGF-1 signaling in neurodegenerative diseases. J Neurochem. 2021;159(2):256-276](https://pubmed.ncbi.nlm.nih.gov/34133725/). 2021. ↩︎
Chen Y, et al. Targeted delivery of neurotrophic factors to the brain. Adv Drug Deliv Rev. 2018;130:89-100. 2018. ↩︎
Kells AP, et al. [AAV2-mediated GDNF gene therapy. Mol Ther. 2010;18(2):387-392](https://pubmed.ncbi.nlm.nih.gov/19953087/). 2010. ↩︎
Sevigny JJ, et al. Neurotrophin small molecule mimetics. Nat Rev Drug Discov. 2016;15(7):516-534. 2016. ↩︎